Working in partnership with the Arkansas Racing Commission and the Arkansas HBPA (Horsemen's Benevolent and Protective Association), Oaklawn has announced, subject to regulatory approval, the prohibition of Clenbuterol or any other beta2-agonist within 120 days of a race. This restriction is part of Oaklawn's ongoing commitment to enhancing the safety and integrity of its racing program.
Conducted by Industrial Labs, the presence of Clenbuterol and other beta2-agonist will be determined through blood, urine and hair follicle testing.
“Banning the use of Clenbuterol and other beta2-agonists further proves our commitment to the safety and integrity of our racing program,” said Oaklawn President Louis Cella. “Every decision we make is to enhance the experience of our horsemen and fans at Oaklawn. When we say “Racing First,' we lead by example.”
Oaklawn's 2021-2022 season runs from Friday, Dec. 3 to Sunday, May 8. The schedule features a total of 36 stakes worth $12,300,000, highlighted by the $1.25 million Arkansas Derby (G1) and three $1 million stakes races – $1 million Rebel Stakes (G2), $1 million Oaklawn Handicap (G2) and $1 million Apple Blossom Handicap (G1). All allowance races will be worth a minimum of $100,000 as part of the richest purse structure in Oaklawn's 118-year history.
The post Oaklawn Renews Commitment To Clenbuterol-Free Racing appeared first on Horse Racing News | Paulick Report.
